CEO, TScan Therapeutics
David Southwell is the Chief Executive Officer of TScan Therapeutics, a discovery-stage company focused on finding cognate antigen targets to specific T cell receptors (TCRs). Previously, Mr. Southwell served as President and Chief Executive Officer of Inotek Pharmaceuticals until its merger with Rocket Pharmaceuticals in January 2018, leading Inotek's IPO, two secondary offerings and the ultimate merger into Rocket. He was Executive Vice President, Chief Financial Officer of Human Genome Sciences until its 2012 merger with GlaxoSmithKline plc. Prior to Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor for fifteen years, and as an investment banker at Lehman Brothers. Mr. Southwell currently serves on the Board of Directors of PTC Therapeutics, Rocket Pharmaceuticals, Spero Therapeutics and TScan Therapeutics. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the MBA Advisory Board and currently serves on the Board of Overseers.